-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The emergence of anti-tumor necrosis factor (TNF) drugs has completely changed the treatment mode of patients with inflammatory bowel disease (IBD).
medsci.
In patients with Crohn's disease, this cut-off value (500 pg/ml TNF) identifies responders with 100% sensitivity and 82% specificity.
This study found that PBMC (especially CD14 + cells) of patients with IBD produce high levels of TNF, which can identify patients who are most likely to have a clinical response to infliximab treatment.
This study found that the PBMC (especially CD14 + cells) of patients with IBD produce high levels of TNF, which can identify patients who are most likely to have a clinical response to infliximab treatment.
Original source:
Bosse Jessen.
Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.
Leave a message here